Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Dec 19, 2016The patents significantly broaden protection for the technology--and for its use to treat a wide variety of diseases
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that it has received five...
- Nov 29, 2016In wide-ranging interview, Hava discusses advances in treating respiratory diseases using inhaled drugs, among other topics
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that its Chief Scientific...
- Nov 4, 2016
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced it third quarter financial...
- Oct 11, 2016New study shows that Pulmatrix's inhaled drug delivery platform successfully delivers higher doses of an antifungal drug to the lungs compared to oral delivery.
Pulmatrix, Inc. (NASDAQ: PULM) will present promising new preclinical data about its inhaled antifungal drug PUR1900 in a poster at the North American Cystic Fibrosis Conference. "The preclinical...
- Oct 3, 2016Dr. Sherman's extensive experience in developing drugs in oncology and other therapeutic areas will help Pulmatrix target more diseases, potentially including cancer.
Pulmatrix, Inc. (NASDAQ: PULM), a pharmaceutical company developing innovative inhaled drugs, announced today that the company has appointed Matthew L. Sherman, M.D., Executive Vice President and...
- Sep 23, 2016Recent white paper by Envigo explains the advantages of delivering drugs to the lungs--and describes how this delivery method is increasingly being used for a wide variety of diseases
Pulmatrix, Inc. (NASDAQ: PULM) today announced that a recent white paper, What is the future of inhalation delivery?, by global research and consulting firm Envigo predicts rapid growth for drugs...
- Sep 7, 2016
Pulmatrix, Inc. (NASDAQ: PULM) will give a presentation at the 2016 Aegis Growth Conference at The Encore at Wynn Las Vegas in Nevada on Wednesday, September 21, 2016 at 10:00 AM PDT. Pulmatrix...
- Aug 31, 2016
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Monday, September 12, 2016 at 5:30 PM EDT in the Lotte New York Palace Hotel in New...
- Aug 17, 2016The designation by the FDA is based on the hypothesis that Pulmatrix's drug may be superior to existing treatments. It creates a quicker regulatory path to market while also providing financial incentives.
Pulmatrix, Inc. (NASDAQ: PULM) announced today that the U.S. Food & Drug Administration has granted the company's request for orphan drug status for its inhaled drug for treating pulmonary fungal...
- Aug 4, 2016
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter financial results and provides an update on the progress of its drug development pipeline. "In the first half of the year, we...
